DE102015207036A1 - Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften - Google Patents

Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften Download PDF

Info

Publication number
DE102015207036A1
DE102015207036A1 DE102015207036.0A DE102015207036A DE102015207036A1 DE 102015207036 A1 DE102015207036 A1 DE 102015207036A1 DE 102015207036 A DE102015207036 A DE 102015207036A DE 102015207036 A1 DE102015207036 A1 DE 102015207036A1
Authority
DE
Germany
Prior art keywords
arenavirus
virus
carcinoma
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE102015207036.0A
Other languages
German (de)
English (en)
Inventor
Anmelder Gleich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abalos Therapeutics GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE102015207036.0A priority Critical patent/DE102015207036A1/de
Priority to BR112017022022-9A priority patent/BR112017022022B1/pt
Priority to US15/567,343 priority patent/US20180117137A1/en
Priority to EP16717129.7A priority patent/EP3283104B1/de
Priority to CN201680030624.5A priority patent/CN108025054B/zh
Priority to PCT/EP2016/058347 priority patent/WO2016166285A1/de
Priority to CA2982873A priority patent/CA2982873A1/en
Priority to HK18110658.2A priority patent/HK1251168B/xx
Priority to JP2018505536A priority patent/JP7039037B2/ja
Priority to ES16717129T priority patent/ES3017684T3/es
Publication of DE102015207036A1 publication Critical patent/DE102015207036A1/de
Priority to US16/267,095 priority patent/US11801294B2/en
Priority to JP2021088871A priority patent/JP7273102B2/ja
Priority to US18/385,250 priority patent/US12409217B2/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE102015207036.0A 2015-04-17 2015-04-17 Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften Pending DE102015207036A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE102015207036.0A DE102015207036A1 (de) 2015-04-17 2015-04-17 Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
HK18110658.2A HK1251168B (en) 2015-04-17 2016-04-15 Arenavirus for use in treatment of tumors in human
JP2018505536A JP7039037B2 (ja) 2015-04-17 2016-04-15 腫瘍の治療および/または阻止において使用するためのアレナウイルス(arenaviruses)、および、(改善された)腫瘍退縮特性(tumor-regression properties)を有するアレナウイルス(arenaviruses)を産生するための方法
EP16717129.7A EP3283104B1 (de) 2015-04-17 2016-04-15 Arenaviren zur anwendung bei der behandlung eines tumors beim menschen
CN201680030624.5A CN108025054B (zh) 2015-04-17 2016-04-15 用于治疗和/或预防肿瘤的沙粒病毒和用于制备具有(改善的)肿瘤消退性能的沙粒病毒的方法
PCT/EP2016/058347 WO2016166285A1 (de) 2015-04-17 2016-04-15 Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften
CA2982873A CA2982873A1 (en) 2015-04-17 2016-04-15 Arenaviruses for use in the treatment and/or prevention of tumors
BR112017022022-9A BR112017022022B1 (pt) 2015-04-17 2016-04-15 Uso de um vírus da coriomeningite linfocítica (lcmv) ou um vírus junin e composição compreende os mesmos
US15/567,343 US20180117137A1 (en) 2015-04-17 2016-04-15 Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (improved) tumor-regression properties.
ES16717129T ES3017684T3 (en) 2015-04-17 2016-04-15 Arenavirus for use in treatment of tumors in human
US16/267,095 US11801294B2 (en) 2015-04-17 2019-02-04 Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV)
JP2021088871A JP7273102B2 (ja) 2015-04-17 2021-05-27 腫瘍の治療および/または阻止において使用するためのアレナウイルス(arenaviruses)、および、(改善された)腫瘍退縮特性(tumor-regression properties)を有するアレナウイルス(arenaviruses)を産生するための方法
US18/385,250 US12409217B2 (en) 2015-04-17 2023-10-30 Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102015207036.0A DE102015207036A1 (de) 2015-04-17 2015-04-17 Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften

Publications (1)

Publication Number Publication Date
DE102015207036A1 true DE102015207036A1 (de) 2016-10-20

Family

ID=55759589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102015207036.0A Pending DE102015207036A1 (de) 2015-04-17 2015-04-17 Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften

Country Status (8)

Country Link
US (3) US20180117137A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283104B1 (cg-RX-API-DMAC7.html)
JP (2) JP7039037B2 (cg-RX-API-DMAC7.html)
CN (1) CN108025054B (cg-RX-API-DMAC7.html)
CA (1) CA2982873A1 (cg-RX-API-DMAC7.html)
DE (1) DE102015207036A1 (cg-RX-API-DMAC7.html)
ES (1) ES3017684T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016166285A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11801294B2 (en) 2015-04-17 2023-10-31 Abalos Therapeutics Gmbh Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017076988A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
DE102018215551A1 (de) * 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
WO2022180203A1 (en) 2021-02-26 2022-09-01 Abalos Therapeutics Gmbh New virus particles for therapeutic purposes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008074A1 (de) 2004-07-16 2006-01-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren
WO2009083210A1 (en) 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors
WO2011056993A1 (en) * 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994221B2 (en) * 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008074A1 (de) 2004-07-16 2006-01-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren
WO2009083210A1 (en) 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors
WO2011056993A1 (en) * 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHENG B. J. Y. et al.: Generation of recombinant Arenavirus for vaccine development in FDA approved Vero cells. In: JOVE - Journal of Visualized Experiments. 2013, 78, e50662 S1-9, - doi: doi:10.3791/50662 unter URL: http://www.jove.com/video/50662 *
KELLY, E.; RUSSEL, S. J.: History of oncolytic viruses: genesis to genetic engineering. In: Molecular Therapy. 2007, Vol. 15 No. 4, S.651-659 *
KELLY, E.; RUSSEL, S. J.: History of oncolytic viruses: genesis to genetic engineering. In: Molecular Therapy. 2007, Vol. 15 No. 4, S.651–659
KOHLER M. et al.: Enhanced tumor susceptibility of immunocompetent mice infected with lympholytic choriomeningitis virus. In: Cancer Immunol. Immunother, 1990, 32, S. 117 -124. *
KOHLER M. et al.: Enhanced tumor susceptibility of immunocompetent mice infected with lympholytic choriomeningitis virus. In: Cancer Immunol. Immunother, 1990, 32, S. 117 –124.
Publikation "Development of replication-defective lymphocytic +choriomeningitis virus vectors for the induction of potent CD8 T cell immunity" (Nature Medicine, Bd. 16, Nr. 3, März 2010, S. 339–345; doi: 10.1038/nm.2104)
SOUTHAM, C. M.; MOORE, A. E.: Clinical studies of viruses as antineoplastic agents, with particular reference to egypt 101 virus. In: Cancer, 1952, Vol.5, S 1025-1034. doi: 10.1002/1097-0142(195209)5:5 *
SOUTHAM, C. M.; MOORE, A. E.: Clinical studies of viruses as antineoplastic agents, with particular reference to egypt 101 virus. In: Cancer, 1952, Vol.5, S 1025–1034. doi: 10.1002/1097-0142(195209)5:5
WEBB, H. E. [et al.]: The treatment of 18 cases of malignant disease with an arenavirus. In: Clinical Oncology, Vol. 1, 1975, No. 2, S. 157-169. - ISSN 0305-7399 *
ZAPATA; J. C.; SALVATO, M. S.: Arenavirus variations due to host-specific adaptation. In: Viruses, 2013, 5, S.241-278, - doi:10.3390/v5010241 unter URL: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3564120/ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11801294B2 (en) 2015-04-17 2023-10-31 Abalos Therapeutics Gmbh Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV)

Also Published As

Publication number Publication date
EP3283104A1 (de) 2018-02-21
CN108025054B (zh) 2022-12-23
BR112017022022A8 (pt) 2023-03-07
JP7039037B2 (ja) 2022-03-22
JP7273102B2 (ja) 2023-05-12
CN108025054A (zh) 2018-05-11
JP2021129589A (ja) 2021-09-09
CA2982873A1 (en) 2016-10-20
US11801294B2 (en) 2023-10-31
US20190151436A1 (en) 2019-05-23
WO2016166285A1 (de) 2016-10-20
ES3017684T3 (en) 2025-05-13
HK1251168A1 (zh) 2019-01-25
JP2018515130A (ja) 2018-06-14
EP3283104C0 (de) 2024-12-11
US12409217B2 (en) 2025-09-09
US20240252611A1 (en) 2024-08-01
BR112017022022A2 (pt) 2019-01-22
US20180117137A1 (en) 2018-05-03
EP3283104B1 (de) 2024-12-11

Similar Documents

Publication Publication Date Title
EP3283104B1 (de) Arenaviren zur anwendung bei der behandlung eines tumors beim menschen
EP2597154B1 (de) LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virusproduzentenzellen zur Therapie von Tumoren
DE69426841T2 (de) Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
DE60026554T2 (de) Onkolytisches vesicular stomatitis virus
JP6327647B2 (ja) 炎症性疾患の予防又は治療用組成物
DE69726759T2 (de) Cytopatische viren zur therapie und prophylaxe der neoplasie
WO2003035870A1 (de) Medikament zur behandlung eines pankreaskarzinoms
DE102018215551A1 (de) Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
EP0748374A1 (de) Verfahren zur herstellung von klonogenen fibroblasten, verfahren zur gentransfizierung von fibroblasten und so erhaltene gentransfizierte fibroblasten
Quan et al. Hydralazine plays an immunomodulation role of pro-regeneration in a mouse model of spinal cord injury
DE202022003066U1 (de) Genetische Modifikation von Säugerzellen zur Verleihung von Resistent gegen CSF1R-Antagonisten
DE10230996A1 (de) Medikament zur Behandlung eines Pankreaskarzinoms
DE112024002330T5 (de) Krebsantigene
EP3140398B1 (de) Tal-effektornuklease zum gezielten knockout des hiv-korezeptors ccr5
WO2011131703A1 (de) Genetisch modifiziertes sendaivirus zur behandlung von tumorerkrankungen
EP2928482B1 (de) Verbesserung der zielfindungskapazität von stammzellen
DE102013105144A1 (de) Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
DE112023003202T5 (de) Rekombinanter Expressionsvektor zur Sekretion von Interleukin-21 und damit transformierter abgeschwächter Salmonellenstamm
DE3883696T2 (de) Anti-Krebs-Mittel und Reagenz zur Gewinnung von Revertanten.
HK1251168B (en) Arenavirus for use in treatment of tumors in human
WO1998042338A1 (de) Verlängerung der expression von transgenen proteinen durch immunmodulierende behandlung
DE19711803A1 (de) Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung mit 15-Deoxyspergualin
DE102008031040A1 (de) Iressa zur Anwendung in der Organtransplantation

Legal Events

Date Code Title Description
R163 Identified publications notified
R082 Change of representative

Representative=s name: SCHIWECK WEINZIERL KOCH PATENTANWAELTE PARTNER, DE

R081 Change of applicant/patentee

Owner name: ABALOS THERAPEUTICS GMBH, DE

Free format text: FORMER OWNER: LANG, KARL SEBASTIAN, PROF. DR., 45147 ESSEN, DE

Owner name: VIROLUTIONS BIOTECH GMBH, DE

Free format text: FORMER OWNER: LANG, KARL SEBASTIAN, PROF. DR., 45147 ESSEN, DE

R082 Change of representative

Representative=s name: SCHIWECK WEINZIERL KOCH PATENTANWAELTE PARTNER, DE

R081 Change of applicant/patentee

Owner name: ABALOS THERAPEUTICS GMBH, DE

Free format text: FORMER OWNER: VIROLUTIONS BIOTECH GMBH, 45130 ESSEN, DE

R012 Request for examination validly filed
R081 Change of applicant/patentee

Owner name: ABALOS THERAPEUTICS GMBH, DE

Free format text: FORMER OWNER: ABALOS THERAPEUTICS GMBH, 45130 ESSEN, DE